Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy–associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1–placental growth factor ratio in the early second trimester

Huang, Tianhua; Rashid, Shamim; Priston, Megan; Rasasakaram, Evasha; Mak-Tam, Ellen; Gibbons, Clare; Mei‐Dan, Elad; Bedford, H. Melanie

doi:10.1016/j.xagr.2023.100193

Cited by 3 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Dutch women did not like the idea of using medication in case they were screened positive, which differs from our study, where 94.3% would take medicine if they were at high risk of developing PE. In a recent Canadian study 23 of satisfaction with PE screening was evaluated postpartum, 93% of participants reported high levels of satisfaction (70–100%) and 98% stated that they would recommend the screening to all pregnant women. Almost all participants in our questionnaire survey said that they would participate in a risk assessment of PE if they had the opportunity and most thought that screening for PE should be offered to all women in Denmark.…”

Section: Discussionmentioning

confidence: 99%

Motivation towards first trimester screening for preeclampsia among pregnant women in Denmark: A cross‐sectional questionnaire study

Gerdes

Ekelund

Rode

et al. 2023

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

IntroductionThe aim of this cross‐sectional questionnaire study was to investigate motivation to participate in a possible new screening for preeclampsia in the first trimester of pregnancy among Danish pregnant women through a questionnaire based on Theory of Planned Behavior developed for this specific purpose. The new screening combines maternal characteristics with mean arterial pressure, uterine artery pulsatility index and biochemical markers to predict the risk of preeclampsia, whereas the current Danish screening uses maternal characteristics alone.Material and methodsParticipation was offered to a proportion of women attending a first or a second trimester screening scan at two University Hospitals in Copenhagen. The questionnaire was set up in REDCap® and answers were entered directly into the database, which was accessed via a QR‐code.ResultsWe invited 772 pregnant women to participate in the questionnaire survey between November 2021 and April 2022 at Copenhagen University Hospital Rigshospitalet (study site one) (n = 238) and Copenhagen University Hospital Hvidovre (study site two) (n = 534). The response rate was 71.8% (171/238) at study site one and 33.9% (181/534) at study site two. A total of 352 women were included in the study (total participation rate 45.6%). Most women had a positive attitude towards preeclampsia screening in pregnancy, and 99.4% said they would participate in a risk assessment for preeclampsia if given the opportunity. A total of 97.4% answered “yes” to whether a first trimester preeclampsia screening should be offered to all pregnant women in Denmark. Positive motivation to participate in preeclampsia screening was correlated with having a network with a positive attitude towards preeclampsia screening.ConclusionsThe results of this study indicate that Danish pregnant women have a positive attitude towards participation in a first trimester screening for preeclampsia. This observation might be useful in relation to possible future implementation in Denmark.

show abstract

Section: Discussionmentioning

confidence: 99%

Motivation towards first trimester screening for preeclampsia among pregnant women in Denmark: A cross‐sectional questionnaire study

Gerdes

Ekelund

Rode

et al. 2023

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…In the realm of predictive and diagnostic tools, placental growth factor and PAPP-A show promise in anticipating the onset of pre-eclampsia. Utilizing these biomarkers holds potential for early diagnosis and effective management of this complex condition [ 15 ].…”

Section: Reviewmentioning

confidence: 99%

“…However, an alternative study suggested that substituting PAPP-A for PlGF diminishes the efficacy of screening for preterm pre-eclampsia [ 50 ]. Furthermore, maternal serum levels of sFlt-1, PlGF, and PAPP-A have been correlated with late-onset pre-eclampsia and IUGR [ 15 ]. PlGF, recognized as a potent angiogenic factor, is crucial in stimulating angiogenesis in various conditions, such as heart and limb ischemia [ 51 ].…”

Section: Reviewmentioning

confidence: 99%

“…Its expression is notably downregulated in pre-eclampsia, contrasting with increased levels observed in cases of IUGR [ 51 ]. PAPP-A has been associated with the development of pre-eclampsia, with higher levels identified in pregnant women affected by pre-eclampsia compared to those without the condition [ 15 ]. Additionally, the use of aspirin (150 mg/day) has demonstrated efficacy in reducing the risk of pre-eclampsia in high-risk women [ 52 ].…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling the Predictive Power: Placenta Growth Factor and Pregnancy-Associated Plasma Protein A in Pre-eclampsia

Singh Thakur,

Tayade,

Patel

et al. 2024

Cureus

View full text Add to dashboard Cite

This review provides a comprehensive exploration of the roles of placenta growth factor (PlGF) and pregnancy-associated plasma protein A (PAPP-A) in the context of pre-eclampsia, a pregnancy-related hypertensive disorder with significant implications for maternal and fetal health. The background elucidates the clinical significance of pre-eclampsia, highlighting its prevalence and impact. The review delves into the biological importance of PlGF and PAPP-A, emphasizing their critical roles in normal placental development and their dysregulation in pre-eclampsia. Notably, altered levels of these biomarkers emerge as potential diagnostic indicators, offering insights into the pathophysiology of the disorder. The exploration of pathophysiological mechanisms, including angiogenic imbalance and placental dysfunction, provides a nuanced understanding of pre-eclampsia's molecular landscape. The therapeutic implications of targeting PlGF and PAPP-A open avenues for future research, aiming at effective intervention strategies. The conclusion summarizes key findings, outlines implications for future research, and underscores the crucial role of PlGF and PAPP-A in understanding and managing pre-eclampsia, with the ultimate goal of improving outcomes for both mothers and infants.

show abstract

“…Another significant study [70] showed that PAPP-A and PlGF MoMs (Multiples of Median) values were significantly reduced among early-onset PE cases (0.57 and 0.60), followed by preterm PE (0.63 and 0.67), all PE (0.74 and 0.74), and gestational hypertension (0.89 and 0.86) cases relative to controls (0.99 and 1.00) for first-trimester PAPP-A and PlGF, respectively. In addition, the study also displayed that a combination of maternal characteristics and PAPP-A and PlGF can provide reasonable performance for PE screening in the first trimester.…”

Section: Soluble Endoglin (Seng)mentioning

confidence: 99%

From Biomarkers to the Molecular Mechanism of Preeclampsia—A Comprehensive Literature Review

Rybak-Krzyszkowska,

Staniczek,

Kondracka

et al. 2023

IJMS

View full text Add to dashboard Cite

Preeclampsia (PE) is a prevalent obstetric illness affecting pregnant women worldwide. This comprehensive literature review aims to examine the role of biomarkers and understand the molecular mechanisms underlying PE. The review encompasses studies on biomarkers for predicting, diagnosing, and monitoring PE, focusing on their molecular mechanisms in maternal blood or urine samples. Past research has advanced our understanding of PE pathogenesis, but the etiology remains unclear. Biomarkers such as PlGF, sFlt-1, PP-13, and PAPP-A have shown promise in risk classification and preventive measures, although challenges exist, including low detection rates and discrepancies in predicting different PE subtypes. Future perspectives highlight the importance of larger prospective studies to explore predictive biomarkers and their molecular mechanisms, improving screening efficacy and distinguishing between early-onset and late-onset PE. Biomarker assessments offer reliable and cost-effective screening methods for early detection, prognosis, and monitoring of PE. Early identification of high-risk women enables timely intervention, preventing adverse outcomes. Further research is needed to validate and optimize biomarker models for accurate prediction and diagnosis, ultimately improving maternal and fetal health outcomes.

show abstract

Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy–associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1–placental growth factor ratio in the early second trimester

Cited by 3 publications

References 36 publications

Motivation towards first trimester screening for preeclampsia among pregnant women in Denmark: A cross‐sectional questionnaire study

Motivation towards first trimester screening for preeclampsia among pregnant women in Denmark: A cross‐sectional questionnaire study

Unraveling the Predictive Power: Placenta Growth Factor and Pregnancy-Associated Plasma Protein A in Pre-eclampsia

From Biomarkers to the Molecular Mechanism of Preeclampsia—A Comprehensive Literature Review

Contact Info

Product

Resources

About